Safety concerns on the development of novel therapeutic drugs

Arthritis Research and Therapy

Volumn 8, Issue 5, 2006, Pages

  Ospelt, Caroline ^a   Gay, Steffen ^a  

^a Center of Experimental Rheumatology   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; MONOCLONAL ANTIBODY CD28; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CELL SELECTION; DNA MICROARRAY; DRUG EFFECT; DRUG EFFICACY; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE THERAPY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOMODULATION; JUVENILE RHEUMATOID ARTHRITIS; MEDICAL INFORMATION; MICROARRAY ANALYSIS; NONHUMAN; NOTE; PHARMACOGENOMICS; PROMOTER REGION; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTOMICS; UNSPECIFIED SIDE EFFECT; VALIDITY; DRUG DESIGN; DRUG INDUSTRY; IMMUNOTHERAPY; PROCEDURES; SAFETY; STANDARDS;

DRUG DESIGN; DRUG INDUSTRY; HUMANS; IMMUNOTHERAPY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SAFETY;

EID: 33750805780     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2032     Document Type: Note

References (13)

1. Feldmann M, Brennan FM, Williams RO, Woody JN, Maini RN: The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2004, 18: 59-80.
2. Ospelt C, Neidhart M, Gay RE, Gay S: Gene analysis for exploring the effects of drugs in rheumatoid arthritis. Arthritis Rheum 2005, 52:2248-2256.
3. Haupl T, Krenn V, Stuhlmuller B, Radbruch A, Burmester GR: Perspectives and limitations of gene expression profiling in rheumatology: new molecular strategies. Arthritis Res Ther 2004, 6:140-146.
4. Jarvis JN, Dozmorov I, Jiang K, Frank MB, Szodoray P, Alex P, Centola M: Novel approaches to gene expression analysis of active polyarticular juvenile rheumatoid arthritis. Arthritis Res Ther 2004, 6:R15-R32.
5. Deng MC, Eisen HJ, Mehra MR, Billingham M, Marboe CC, Berry G, Kobashigawa. J, Johnson FL, Starling RC, Murali S, et al.: Non-invasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006, 6: 150-160.
6. Hopkin M: Can super-antibody drugs be tamed? Nature 2006, 440:855-856.
7. Thomsen M, Yacoub-Youssef H, Marcheix B: Reconstitution of a human immune system in immunodeficient mice: models of human alloreaction in vivo. Tissue Antigens 2005, 66:73-82.
8. Ranganathan P, McLeod HL: Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum 2006, 54:1366-1377.
9. Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D: Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 2005,52:2693-2696.
10. Schotte H, Schluter B, Drynda S, Willeke P, Tidow N, Assmann G, Domschke W, Kekow J, Gaubitz M: Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann Rheum Dis 2005, 64:575-581.
11. Fabris M, Tolusso B, Di Poi E, Assaloni R, Sinigaglia L, Ferraccioli G: Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. J Rheumatol 2002, 29:1847-1850.
12. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D: Polymorphism at position - 308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003, 48:1849-1852.
13. Department of Health: Expert Scientific Group on phase one clinical trials: a consultation [http://www.dh.gov.uk/Consultations/ LiveConsultations/LiveConsultationsArticle/fs/en?CONTENT_ID=4137501 &chk=x%2BoJ%/2B]